A new therapeutic target to fight metastasis in ovarian cancer

January 04, 2018

Researchers of the Molecular Signaling in Cancer group of the Oncobell program (Bellvitge Biomedical Research Institute - IDIBELL) - proCURE Program (Catalan Institute of Oncology - ICO) have described a key cellular receptor in the processes of metastasis in ovarian cancer. The finding, published in Molecular Cancer Therapeutics, might lead to the use of inhibitors of this receptor as a therapeutic target in the most aggressive variants of the disease, in which a differential expression has been found.

The IDIBELL-ICO research team has succeeded in associating the expression of the CXCR4 receptor in ovarian tumor cells to their dissemination potential through the bloodstram. CXCR4 is a receptor involved in blood cell movement, which had previously been related to processes of dissemination in breast cancer.

In studies in orthotopic models, the researchers proved that administration of CXCR4 inhibitors in cancers where high expression of this receptor had previously been detected greatly decreased the propagation of the tumor cells at the blood level and within the peritoneum. At the same time, they have also observed that the genetic elimination of CXCR4 in cell culture gives rise to tumors with slower growth and a lower percentage of dissemination.

The diagnosis of ovarian cancer usually comes late; in 80% of cases, patients already show metastases or peritoneal disseminations that can affect vital organs of the digestive, circulatory or renal systems. On the other hand, although it is true that the combination of surgery and chemotherapy with platinum derivatives works very well, the percentage of recurrence of the disease at two years is 70%.

The IDIBELL-ICO researchers believe that studyng the dissemination patterns of tumor cells is essential in order to understand and improve the prognosis of the disease. Their line of research focuses on identifying the molecules involved in this dissemination, which usually presents itself together with an abnormal buildup of fluid in the abdomen (ascites). "If we identify the factors that drive movement and implantation of tumor cells in new organs, we can try to block them in order to minimize the chances of metastasis; CXCR4 is not the only factor, but we have proved that it is one of them", says Dr. Agnès Figueras, first author of the study.
-end-


IDIBELL-Bellvitge Biomedical Research Institute

Related Ovarian Cancer Articles from Brightsurf:

Ovarian cancer cells cooperate to metastasize
In a study on human ovarian cancer cells in mice, Harvard Medical School researchers discovered a transient, cooperative interaction between cell subpopulations that allows otherwise nonmetastatic tumor cells to become aggressive and spread.

Photodynamic therapy used to treat ovarian cancer
Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.

Studying the development of ovarian cancer with organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions, or organoids, of the female reproductive organs of the mouse.

New class of drugs could treat ovarian cancer
A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

How to catch ovarian cancer earlier
Ovarian cancer is often diagnosed too late for effective treatment.

New compound could help treat ovarian cancer
Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.

Epigenetic markers of ovarian cancer
Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.

Ovarian cancer statistics, 2018
A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.

Read More: Ovarian Cancer News and Ovarian Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.